Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of bevacizumab + atezolizumab + platinum-etoposide versus placebo + atezolizumab + platinum-etoposide in untreated extensive-stage small cell lung cancer
CTR20210041Phase 3Terminated
- Sponsor
- Roche
- Start
- Jan 2021
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of bevacizumab, atezolizumab, carboplatin, cisplatin, etoposide in small cell lung cancer (SCLC), sponsored by Roche. Started Jan 2021; status: terminated.
02
Drugs
bevacizumabatezolizumabcarboplatincisplatinetoposide
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20210041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210041.